Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia

NovartisNovartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign. Zambia is the first beneficiary country of this campaign sponsored by Novartis. One million treatments of Coartem® Dispersible have been funded through public donations and Novartis matched these with a further one million treatments. These antimalarials will reduce the disease burden in Zambia, which accounts for up to 40% of infant mortality in that country[2].

"Although the incidence of malaria has decreased, the disease still kills a child every minute in Africa," said Joseph Jimenez, CEO of Novartis. "Our commitment to Power of One reflects our company's long-term efforts to fight malaria and Novartis remains dedicated to controlling and ultimately eliminating this deadly disease."

Power of One is a global digital fundraising campaign that enables people around the world to help end child deaths from malaria, a preventable and treatable disease. This fatal disease has been recognized by the World Health Organization as a priority area of public health. This year's World Health Day focuses on vector-borne diseases, and malaria is the most deadly[1].

The campaign, which launched to the public in September 2013, uses social, mobile, and e-commerce technologies, enabling the public to purchase treatments for children in Zambia. Donors are able to share information with their social networks and encourage friends to donate.

"One and a half million treatments are already on the ground in Zambia thanks to the Power of One campaign, with a further 500,000 anticipated in the coming weeks," said Martin Edlund, CEO, Malaria No More. "Power of One is resonating with the general public, and their donations will help us ensure that children in Zambia will have access to the treatment they need."

Novartis is supporting the campaign financially and has pledged to match up to 1 million treatments funded by the public every year through 2015. For more than a decade, the Novartis Malaria Initiative has worked to improve access to treatment, help communities deliver better healthcare and has invested in research and development into the next generation of antimalarials. Since 2009, Novartis has delivered over 600 million treatments, of which more than 200 million were treatments developed specifically for children, without profit to malaria-endemic countries. Never before have so many pediatric treatments been distributed in such a short timeframe to children suffering from malaria[3].

About Power of One
Malaria No More's Power of One campaign offers the global public and corporations the opportunity to help end malaria deaths one dollar and one child at a time. Every dollar donated funds a full treatment course for a child diagnosed with malaria in Africa. Malaria No More is grateful for the support and contributions of Power of One partners: Novartis, Alere, the Zambian Government, 21st Century Fox, AGFUND, AHAlife.com, the Bill & Melinda Gates Foundation, Causes.com, Havas Worldwide, John Snow, Inc., Newman's Own Foundation, PATH/MACEPA, Peace Corps, Time Warner, Twitter, the United States President's Malaria Initiative, Venmo, West, and more.

About the Novartis Malaria Initiative
The Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry. Moving forward, Novartis is committed to working towards malaria elimination by driving the development of next-generation antimalarials, with two new classes of drugs currently in clinical development. The most advanced compound is in Phase II clinical trials.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world.

1. World Health Organization. World Health Day - 7 April 2014. http://www.who.int/campaigns/world-health-day/2014/event/en/ [last accessed February 2014]
2. Malaria No More. Zambia. https://secure.malarianomore.org/po1#/pages/zambia [last accessed February 2014]
3. Malaria No More. Power of One. https://secure.malarianomore.org/po1#/pages/about-power-of-one [last accessed February 2014]

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]